GILD and MRK Related Headlines
Go Back- Gilead and Merck announce successful HIV treatment trial results
- Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
- Merck and Gilead discontinue lung cancer drug combination trial
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- China holds roundtable with over 50 foreign pharmaceutical firms
- Bernstein on US Pharma and Biotech: Who might buy whom?
- Barclays launches U.S. biopharma coverage with four preferred picks
- 14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
- Trump to announce prescription drug price agreements
- Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
- Trump demands pharma CEOs lower drug prices within 60 days
- Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
- Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
GILD and MRK Related Press Releases
Go Back- Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
